Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
NCT04665739Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2023
- Primary completion
- Sep 2032
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in bronchial neuroendocrine tumor (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 5 years. Started Feb 2023; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
bronchial neuroendocrine tumor
Beyond the preview
Go deeper on NCT04665739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665739.